Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous DC-CIK and NK cell therapy in advanced solid tumors
NCT07260058Phase 2Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Whole Cell Cancer Vaccines, Lymphokine-Activated Killer Cells, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of autologous dendritic cell-cytokine-induced killer cells, autologous natural killer cells in lung cancer, liver cancer, colorectal cancer (CRC), breast cancer. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
autologous dendritic cell-cytokine-induced killer cellsautologous natural killer cells
03
Conditions
lung cancerliver cancercolorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on NCT07260058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260058.